CBD and IBS: what the only published trial shows

Irritable bowel syndrome pairs abdominal pain with changes in bowel habit (diarrhoea, constipation or the two in turn) lasting at least six months. According to the SNFGE, 5% of adults may be affected, three women for every man, and the diagnosis usually comes between the ages of 30 and 40.

Among the approaches the society lists are antispasmodics, the low-FODMAP diet, which seems to help about one person in two, and hypnosis for stubborn cases. CBD does not appear on that list.

Severe forms are a heavy load for the health system. Using French national health insurance data, a 2019 study in BMC Gastroenterology identified 29,509 adults hospitalised for the syndrome in 2015 among 43.7 million insured people. During that stay, 64% of them had a colonoscopy.

The gut has a nervous network of its own. Inserm, the French national health research institute, says this enteric nervous system holds 200 million neurons and exchanges signals with the brain all the time, a link known as the gut-brain axis.

The digestive tract also has cannabinoid receptors, CB1 and CB2, which belong to the endocannabinoid system. According to a 2023 review in Clinical Gastroenterology and Hepatology, cannabinoids generally tend to slow gut motility. This observation led research teams to test CBD in disorders of the gut-brain axis. A hypothesis about a mechanism still falls short of a clinical result.

A PubMed search in September 2026 turns up a single placebo-controlled trial of CBD in this syndrome. A Dutch team published it in 2022 in Cannabis and Cannabinoid Research, as a double-blind crossover trial with a CBD chewing gum. Reports often get the format wrong. Participants used a chewing gum containing 50 mg, chewed on demand when pain came on, up to six a day.

The 32 women enrolled, median age 31, came from Gelderse Vallei hospital in the Netherlands. Over eight weeks they went through one observation week, then two three-week periods (CBD then placebo, or the reverse) separated by a one-week break. The main outcome was the change in pain thirty minutes after chewing, scored from 0 to 10 on a visual scale.

The result is null. CBD and placebo differed by a mean of 0.1 pain point, with a 95% confidence interval from -0.3 to 0.5 (p = 0.61). For quality of life, measured with the IBS-36 questionnaire, the difference was -1.0, with an interval from -6.8 to 4.9 (p = 0.74). Both intervals include zero, so the trial cannot separate CBD from placebo.

The authors themselves note limits that prevent a firm conclusion in either direction. Participants chewed only 0.84 gums a day on average, thirty minutes of chewing proved impractical, and the dose may have been too low. The sample was also small and entirely female. CBD therefore showed no effect at the one dose and in the one format tested, which falls short of proving it ineffective. Our article on what clinical studies really say places this result among other trials.

The first concerns palmitoylethanolamide (PEA). A 2017 trial in Alimentary Pharmacology and Therapeutics tested PEA combined with polydatin in 54 patients over twelve weeks. Its primary, biological outcome did not change, although abdominal pain improved compared with placebo. PEA, however, is a molecule the body makes itself, related to anandamide; it is neither a hemp cannabinoid nor CBD.

The second concerns olorinab. The 2023 review cites a placebo-controlled trial in which it reduced abdominal pain in the constipation-predominant form of the syndrome. Olorinab, though, is a synthetic agonist of the CB2 receptor and has nothing to do with CBD.

The third does concern CBD, in a neighbouring disorder, functional dyspepsia. According to the same review, CBD did not significantly improve pain outcomes there, which makes a second negative result on digestive pain.

The law settles the question of format before science does. In a notice dated 20 May 2026, the French Agriculture Ministry states that foods containing CBD are not authorised under the EU novel food regulation. Only hemp seeds and their derivatives, plus leaves for infusion, remain lawful, and only without added cannabinoids. A CBD chewing gum or an oil to swallow therefore cannot be sold on the open market. This regime is covered in our overview of CBD regulation in 2026.

On 9 February 2026, EFSA published a provisional safe level of 0.0275 mg of CBD per kilogram of body weight per day, about 2 mg a day for a 70 kg adult. A single gum from the Dutch trial held 25 times as much. The agency says safety cannot be established for people under 25, pregnant or breastfeeding women and people on medication. Patients taking antispasmodics or other medicines fall directly under that last point. Our articles on EFSA's reference dose and on drug interactions go into detail.

A CBD product may not claim any therapeutic effect either. MILDECA, the French interministerial drug agency, points out that only authorised medicines may do so. Epidyolex, the only cannabidiol medicine authorised in France, is indicated for certain epilepsies and has no digestive indication.

Mention recurring digestive discomfort to a doctor, since IBS is diagnosed only once other causes have been ruled out. The SNFGE lists warning signs that call for prompt advice and often for tests: blood in the stools, weight loss, marked fatigue, fever, pain at night, or recent symptoms, especially after 50. These signs can point to inflammatory bowel disease or colorectal cancer, and no wellness product should delay finding out.